Puma Biotechnology reports Q EPS 21c, one estimate 9c

Reports Q revenue $54.5M, one estimate $51.0M. “We are very happy to report the continuation of our positive earnings trend, which is driven by increased demand for NERLYNX(R),” said Alan H. Auerbach, Chairman, Chief Executive Officer, and President of Puma. “According to our current projections, 2025 will mark the first year-over-year demand increase for NERLYNX in the United States since 2018 and we are very pleased with our commercial execution, which contributed to this. We are also pleased with our continued clinical progress in the advancement of alisertib for patients facing chemotherapy-naive HER2-negative, hormone receptor-positive metastatic breast cancer in ALISCATM-Breast1 and for patients with extensive-stage small cell lung cancer in ALISCATM-Lung1, where there continues to be a need for new treatment. We anticipate the following key milestones over the next 12 months: (i) presentation of interim data from ALISCA(TM)-Breast1, a Phase II trial of alisertib in combination with endocrine treatment in patients with chemotherapy-naive HER2-negative, hormone receptor-positive metastatic breast cancer (H1 2026) and (ii) presentation of additional interim data from the ALI-4201/ALISCA(TM)-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive stage small cell lung cancer (H1 2026).”